Los Angeles Capital Management
COLL icon

Los Angeles Capital Management’s Collegium Pharmaceutical COLL Stock Holding History

Los Angeles Capital Management’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.24M Buy
89,443
+63,602
+246% +$2.17M 0.01% 491
2026
Q1 		$855K Sell
25,841
-14,600
-36% -$618K ﹤0.01% 719
2025
Q4 		$1.44M Sell
40,441
-26,799
-40% -$1.12M ﹤0.01% 525
2025
Q3 		$2.35M Buy
67,240
+17,368
+35% +$604K 0.01% 461
2025
Q2 		$1.47M Sell
49,872
-3,555
-7% -$101K 0.01% 530
2025
Q1 		$1.59M Buy
53,427
+900
+2% +$27.5K 0.01% 448
2024
Q4 		$1.5M Sell
52,527
-4,700
-8% -$156K 0.01% 502
2024
Q3 		$2.21M Sell
57,227
-2,684
-4% -$95.7K 0.01% 435
2024
Q2 		$1.93M Sell
59,911
-6,029
-9% -$209K 0.01% 463
2024
Q1 		$2.56M Sell
65,940
-4,586
-7% -$160K 0.01% 443
2023
Q4 		$2.17M Sell
70,526
-6,350
-8% -$159K 0.01% 465
2023
Q3 		$1.72M Buy
76,876
+585
+0.8% +$13.3K 0.01% 485
2023
Q2 		$1.64M Buy
76,291
+5,023
+7% +$114K 0.01% 532
2023
Q1 		$1.71M Sell
71,268
-21,903
-24% -$581K 0.01% 537
2022
Q4 		$2.16M Sell
93,171
-45,847
-33% -$924K 0.01% 499
2022
Q3 		$2.23M Buy
139,018
+16,120
+13% +$284K 0.01% 480
2022
Q2 		$2.18M Buy
122,898
+23,379
+23% +$393K 0.01% 515
2022
Q1 		$2.03M Buy
+99,519
New +$1.88M 0.01% 530
2021
Q3 		– Sell
-21,871
Closed -$517K – 1491
2021
Q2 		$517K Sell
21,871
-1,200
-5% -$27.7K ﹤0.01% 1150
2021
Q1 		$547K Sell
23,071
-19,850
-46% -$472K ﹤0.01% 1176
2020
Q4 		$860K Sell
42,921
-1,595
-4% -$31.1K ﹤0.01% 1001
2020
Q3 		$927K Sell
44,516
-960
-2% -$17.3K ﹤0.01% 851
2020
Q2 		$796K Buy
45,476
+8,116
+22% +$159K ﹤0.01% 935
2020
Q1 		$610K Buy
+37,360
New +$771K ﹤0.01% 846
2018
Q3 		– Sell
-16,100
Closed -$384K – 1402
2018
Q2 		$384K Buy
+16,100
New +$396K ﹤0.01% 1212

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Los Angeles Capital Management's COLL Position: Q2 2026 in Review

Los Angeles Capital Management increased its Collegium Pharmaceutical (COLL) stake by 246% in Q2 2026, buying an estimated $2.17M and bringing the position to 89,443 shares worth $3.24M. The position accounts for 0.01% of the portfolio, ranked #491.

Los Angeles Capital Management first reported a position in COLL in Q2 2018 and has held it in 25 quarters since. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

  • Los Angeles Capital Management held 89,443 shares of Collegium Pharmaceutical worth $3.24M as of Q2 2026.
  • Los Angeles Capital Management bought 63,602 Collegium Pharmaceutical shares in Q2 2026, an estimated $2.17M.
  • Collegium Pharmaceutical made up 0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #491 holding.
  • Los Angeles Capital Management first reported a position in Collegium Pharmaceutical in Q2 2018 and has held it in 25 quarters since.
  • 279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.